Laprituximab emtansine  (Synonyms: IMGN-289; J2898A-SMCC-DM1)

Laprituximab emtansine (IMGN-289) is an immunotoxin targeting HER1. Laprituximab emtansine is an EGFR antibody-drug conjugate (ADC) consisting of the J2898A antibody, DM1 (anti-microtubule agent) and the SMCC thioether linker. Laprituximab emtansine can be used for cancer research^[1][2][3].

Laprituximab emtansine shows anti-clonogenic and anti-proliferative activities against HNSCC cell lines with IC₅₀s of 0.003 nM-1.74 nM^[3].
Laprituximab emtansine shows cytotoxic activity against a panel of NSCLC cell lines and EGFR mutant HCC827 cell lines^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Laprituximab emtansine (1-5 mg/kg, i.v.) results tumor regression in EGFR-positive SCCHN xenograft model^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1622327-37-0

[Laprituximab emtansine]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Moradi-Kalbolandi S, et al. Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER. J Pharm Pharmacol. 2018 Jul;70(7):841-854.  [Content Brief]

  [2]. Yulius Y. et al. Abstract 4513: IMGN289, an EGFR-targeting antibody-drug conjugate, is effective against tumor cells that are resistant to EGFR tyrosine kinase inhibitors. Cancer Res 1 October 2014; 74 (19_Supplement): 4513.

  [3]. Hyunseok Kang, et al. Antitumor effect of IMGN289, an anti-EGFR antibody-drug conjugate (ADC), in preclinical models of head and neck squamous cell carcinomas (HNSCC). Journal of Clinical Oncology. 2014. 32, no. 15_suppl.

  [4]. Jose F. Ponte, et al. Abstract 5483: Preclinical evaluation of IMGN289, an anti-EGFR antibody-maytansinoid conjugate for the treatment of squamous cell carcinoma of the head and neck. Cancer Res (2013) 73 (8_Supplement): 5483.